RhumbLine Advisers
IMRX icon

RhumbLine Advisers’s Immuneering IMRX Stock Holding History

RhumbLine Advisers’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-3,386
Closed -$4.33K – 4261
2024
Q2 		$4.33K Sell
3,386
-17,546
-84% -$28.8K ﹤0.01% 4106
2024
Q1 		$60.5K Buy
20,932
+909
+5% +$5.09K ﹤0.01% 3584
2023
Q4 		$147K Buy
20,023
+217
+1% +$1.45K ﹤0.01% 3321
2023
Q3 		$152K Buy
19,806
+2,275
+13% +$20.9K ﹤0.01% 3302
2023
Q2 		$178K Buy
+17,531
New +$169K ﹤0.01% 3297
2022
Q2 		– Sell
-13,819
Closed -$89K – 3164
2022
Q1 		$89K Buy
+13,819
New +$133K ﹤0.01% 2907

Other funds holding IMRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SM
Southport Management Wilson, Wyoming $28.6M AUM 41.61% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $123B AUM 34.51% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

RhumbLine Advisers's IMRX Position: Q3 2024 in Review

RhumbLine Advisers sold out of Immuneering (IMRX) in Q3 2024, closing a stake of 3,386 shares — an estimated $4.33K sold.

RhumbLine Advisers first reported a position in IMRX in Q1 2022 and held it in 6 quarters. The position peaked at $178K in Q2 2023. 38 funds tracked by Wall St. Rank hold IMRX as of Q3 2024.

  • RhumbLine Advisers reported no remaining Immuneering position as of Q3 2024 after selling out during the quarter.
  • RhumbLine Advisers sold 3,386 Immuneering shares in Q3 2024, an estimated $4.33K.
  • RhumbLine Advisers first reported a position in Immuneering in Q1 2022 and held it in 6 quarters.
  • RhumbLine Advisers's Immuneering position peaked at $178K in Q2 2023.
  • 38 funds tracked by Wall St. Rank held Immuneering as of Q3 2024.

Based on RhumbLine Advisers's 13F filing for Q3 2024, filed 12 Nov 2024.